Simris Biologics
At Simris, we are pioneering the next generation of ADC payloads to revolutionise cancer treatment. Our platform is built on the world’s largest cyanobacterial strain library and over two decades of deep scientific expertise. Through our proprietary discovery and bioconjugation technologies, we are developing novel, IP-protected payloads with the potential to dramatically improve both the efficacy and safety of ADC therapeutics.
Our next-generation ADC payloads are designed using cyanobacterial toxin engineering, and are built to outperform conventional payloads in potency, safety, and selectivity.
